RXRX
Recursion Pharmaceuticals, Inc.$3.48+0.00 (+0.00%)Prev Close$3.48·MCap$1.57B·P/E—·Vol4.41M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
29
$11.79M
◆
Net Activity
Net Seller
$11.79M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Recursion Pharmaceuticals, Inc. (RXRX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 29 insider sales totaling $11.79M. The most recent insider transaction was by Gibson Christopher (director), who sold $144.4K worth of shares on Apr 24, 2026. Recursion Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.57B.
RXRX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.61 | $144.4K | 906,556 |
| Apr 8, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.10 | $93.0K | 6,229,863 |
| Apr 8, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.10 | $124.0K | 906,556 |
| Mar 25, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.25 | $130.0K | 906,556 |
| Mar 18, 2026 | Taylor Ben R | officer: Chief Financial Officer | Sell | 7,956 | $3.39 | $27.0K | 1,180,318 |
| Mar 11, 2026 | Khan Najat | director, officer: CEO and President | Sell | 28,298 | $3.35 | $94.7K | 2,262,085 |
| Feb 17, 2026 | Gibson Christopher | Director | Sell | 67,265 | $3.47 | $233.6K | 0 |
| Feb 17, 2026 | Hallett David | Chief Scientific Officer | Sell | 11,908 | $3.49 | $41.6K | 0 |
| Feb 17, 2026 | Khan Najat | CEO and President | Sell | 14,280 | $3.49 | $49.8K | 0 |
| Feb 17, 2026 | Taylor Ben R | Chief Financial Officer | Sell | 13,426 | $3.08 | $41.4K | 0 |
| Feb 6, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.20 | $924.0K | 6,429,863 |
| Feb 6, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.12 | $164.8K | 913,839 |
| Jan 22, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.47 | $178.8K | 913,839 |
| Jan 8, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.36 | $959.2K | 6,649,863 |
| Jan 7, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.25 | $170.0K | 933,839 |
| Dec 30, 2025 | Taylor Ben R | Chief Financial Officer | Sell | 21,383 | $4.18 | $89.4K | 761,550 |
| Dec 29, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 124,403 | $4.41 | $548.6K | 611,135 |
| Dec 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.50 | $180.0K | 913,839 |
| Dec 5, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.63 | $185.2K | 933,839 |
| Dec 4, 2025 | Borgeson Blake | Director | Sell | 220,000 | $4.37 | $961.4K | 6,869,863 |
| Nov 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.16 | $166.4K | 913,839 |
| Nov 6, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $5.21 | $208.4K | 974,229 |
| Oct 24, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $5.70 | $570.0K | 954,229 |
| Oct 10, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $6.04 | $604.0K | 974,229 |
| Sep 26, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.76 | $476.0K | 954,229 |
| Sep 12, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.71 | $471.0K | 974,229 |
| Aug 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.84 | $484.0K | 954,229 |
| Aug 19, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 36,599 | $5.52 | $202.2K | 668,197 |
| Aug 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 618,175 | $5.28 | $3.26M | 1,004,619-38% |
| Mar 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 138,574 | $6.04 | $837.0K | 1,117,450 |
| Mar 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.48 | $259.0K | 1,256,024 |
| Feb 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.90 | $316.0K | 1,273,156 |
| Jan 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.18 | $287.2K | 736,633 |
| Dec 6, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.14 | $285.6K | 736,633 |
| Nov 15, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.55 | $301.8K | 762,656 |
| Nov 14, 2024 | Borgeson Blake | Director | Sell | 11,447 | $7.64 | $87.5K | 7,066,113 |
| Nov 14, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $7.65 | $229.5K | 1,499,631 |
| Oct 31, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.72 | $76.9K | 7,077,560 |
| Oct 28, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $6.31 | $37.9K | 521,138 |
| Oct 17, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.67 | $76.3K | 7,089,007 |
| Oct 10, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $6.34 | $190.1K | 1,450,881 |
| Oct 4, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.12 | $244.8K | 762,656 |
| Oct 3, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.22 | $71.2K | 7,098,428 |
| Sep 30, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $7.00 | $42.0K | 521,138 |
| Sep 19, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.84 | $78.3K | 7,109,875 |
| Sep 12, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $6.24 | $187.2K | 1,402,131 |
| Sep 6, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.09 | $243.6K | 762,656 |
| Sep 5, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.27 | $71.7K | 7,121,322 |
| Sep 3, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $7.56 | $45.4K | 521,138 |
| Aug 22, 2024 | Borgeson Blake | Director | Sell | 11,447 | $7.12 | $81.5K | 7,132,769 |
Showing 1–50 of 225
1 / 5
RXRX Insider Buying Activity
The following table shows recent insider purchases of Recursion Pharmaceuticals, Inc. (RXRX) stock reported via SEC Form 4 filings.
No insider buying activity found for RXRX in the last 12 months.
RXRX Insider Selling Activity
The following table shows recent insider sales of Recursion Pharmaceuticals, Inc. (RXRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.61 | $144.4K | 906,556 |
| Apr 8, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.10 | $93.0K | 6,229,863 |
| Apr 8, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.10 | $124.0K | 906,556 |
| Mar 25, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.25 | $130.0K | 906,556 |
| Mar 18, 2026 | Taylor Ben R | officer: Chief Financial Officer | Sell | 7,956 | $3.39 | $27.0K | 1,180,318 |
| Mar 11, 2026 | Khan Najat | director, officer: CEO and President | Sell | 28,298 | $3.35 | $94.7K | 2,262,085 |
| Feb 17, 2026 | Gibson Christopher | Director | Sell | 67,265 | $3.47 | $233.6K | 0 |
| Feb 17, 2026 | Hallett David | Chief Scientific Officer | Sell | 11,908 | $3.49 | $41.6K | 0 |
| Feb 17, 2026 | Khan Najat | CEO and President | Sell | 14,280 | $3.49 | $49.8K | 0 |
| Feb 17, 2026 | Taylor Ben R | Chief Financial Officer | Sell | 13,426 | $3.08 | $41.4K | 0 |
| Feb 6, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.20 | $924.0K | 6,429,863 |
| Feb 6, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.12 | $164.8K | 913,839 |
| Jan 22, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.47 | $178.8K | 913,839 |
| Jan 8, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.36 | $959.2K | 6,649,863 |
| Jan 7, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.25 | $170.0K | 933,839 |
| Dec 30, 2025 | Taylor Ben R | Chief Financial Officer | Sell | 21,383 | $4.18 | $89.4K | 761,550 |
| Dec 29, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 124,403 | $4.41 | $548.6K | 611,135 |
| Dec 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.50 | $180.0K | 913,839 |
| Dec 5, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.63 | $185.2K | 933,839 |
| Dec 4, 2025 | Borgeson Blake | Director | Sell | 220,000 | $4.37 | $961.4K | 6,869,863 |
| Nov 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.16 | $166.4K | 913,839 |
| Nov 6, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $5.21 | $208.4K | 974,229 |
| Oct 24, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $5.70 | $570.0K | 954,229 |
| Oct 10, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $6.04 | $604.0K | 974,229 |
| Sep 26, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.76 | $476.0K | 954,229 |
| Sep 12, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.71 | $471.0K | 974,229 |
| Aug 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.84 | $484.0K | 954,229 |
| Aug 19, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 36,599 | $5.52 | $202.2K | 668,197 |
| Aug 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 618,175 | $5.28 | $3.26M | 1,004,619-38% |
| Mar 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 138,574 | $6.04 | $837.0K | 1,117,450 |
| Mar 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.48 | $259.0K | 1,256,024 |
| Feb 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.90 | $316.0K | 1,273,156 |
| Jan 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.18 | $287.2K | 736,633 |
| Dec 6, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.14 | $285.6K | 736,633 |
| Nov 15, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.55 | $301.8K | 762,656 |
| Nov 14, 2024 | Borgeson Blake | Director | Sell | 11,447 | $7.64 | $87.5K | 7,066,113 |
| Nov 14, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $7.65 | $229.5K | 1,499,631 |
| Oct 31, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.72 | $76.9K | 7,077,560 |
| Oct 28, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $6.31 | $37.9K | 521,138 |
| Oct 17, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.67 | $76.3K | 7,089,007 |
| Oct 10, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $6.34 | $190.1K | 1,450,881 |
| Oct 4, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.12 | $244.8K | 762,656 |
| Oct 3, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.22 | $71.2K | 7,098,428 |
| Sep 30, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $7.00 | $42.0K | 521,138 |
| Sep 19, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.84 | $78.3K | 7,109,875 |
| Sep 12, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $6.24 | $187.2K | 1,402,131 |
| Sep 6, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.09 | $243.6K | 762,656 |
| Sep 5, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.27 | $71.7K | 7,121,322 |
| Sep 3, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $7.56 | $45.4K | 521,138 |
| Aug 22, 2024 | Borgeson Blake | Director | Sell | 11,447 | $7.12 | $81.5K | 7,132,769 |
RXRX Insiders
Similar Stocks to RXRX
VRTX
Vertex Pharmaceuticals Incorporated
$428.36+0.55%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$739.29-0.68%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$305.75-0.85%
$41.24B
INSM
Insmed Incorporated
$133.16-2.19%
$30.79B
RVMD
Revolution Medicines, Inc.
$145.59+10.58%
$29.51B
UTHR
United Therapeutics Corporation
$566.37-0.28%
$25.13B
MRNA
Moderna, Inc.
$46.93-3.64%
$21.42B
RPRX
Royalty Pharma plc
$49.63-0.02%
$21.20B